Press Room

Event

PhysChem Forum Japan

Start
Thursday, October 16, 2025
End
Thursday, October 16, 2025
Location: Fujisawa, Japan

The PhysChem Forum Japan is recognized for bringing together industry experts to meet and discuss advancements in drug discovery and development.

Hovione team will be available to present our innovative solutions. Connect today and get to know more about our Spray Drying leadership and how we support our customers to overcome solubility issues.

Do not miss the Hovione session, presented by Inês Ramos, R&D Manager, Formulation Development - Oral Drug Product Development

Title: Fast to First-in-Human: a streamlined material sparing approach for Amorphous Solid Dispersion development

Abstract: For BCS II and IV compounds, bioavailability enhancement is driven by absorption enhancement needs, target product profile, and drug molecular features. The manufacturing of Amorphous solid dispersions (ASD) has become an established and commercially demonstrated strategy to improve the bioavailability of such drugs. This lecture will provide an overview of how to design a successful formulation for Amorphous Solid Dispersions produced by spray drying, using a streamlined approach and proprietary technology to expedite time to market. An overview of Hovione’s methodology (staring with ASD-HIPROS), data evaluation process, and the studies applied, insights on alternative excipients (such as Dispersome®), as well as key information needed to make a formal assessment of the best candidates for first-in-human trials will be provided resorting to case-studies.

 

Schedule a meeting today. Let's discuss your project together.

あなたのプロジェクトについて一緒にお話しませんか

 

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

 

 

 

 

Also in the Press Room

See All

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 7 May 2026

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026

Also in Events

See All